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Figure 1
Disease Name Families
reporting
condition
Families reporting
condition/total
families
responding
Transplant indications
Acute lymphoblastic leukemia 145 0.34%
Hodgkin’s lymphoma 144 0.33%
Non-Hodgkin’s lymphoma 141 0.33%
Sarcoma 73 0.17%
Sickle cell disease 54 0.12%
Acute myelogenous leukemia 42 0.10%
Neuroblastoma 40 0.09%
Beta thalassemia major 38 0.09%
Chronic myelogenous leukemia 37 0.09%
Chronic lymphocytic leukemia 32 0.07%
Severe aplastic anemia 22 0.05%
Multiple myeloma 19 0.04%
Myelodysplastic syndrome 10 0.02%
Diamond-blackfan anemia 6 0.01%
Fanconi anemia 4 0.01%
Hurler syndrome 0 0.00%
TOTAL* 807 1.87%
Regenerative indications
Autism/apraxia 1348 3.12%
Diabetes, type 1 1088 2.52%
Diabetes, type II 1044 2.41%
Inﬂammatory bowel disease 1044 2.41%
Other developmental delay 1023 2.36%
Childhood hearing loss 502 1.16%
Cerebral palsy/periventricular
leukomalacia/hypotonia
348 0.80%
Systemic lupus 192 0.44%
Spinal cord injury 154 0.36%
Traumatic brain injury (post-delivery) 139 0.32%
Hydrocephalus 132 0.31%
Hypoxic-ischemic brain injury 128 0.30%
In-utero brain injury/stroke 109 0.25%
Muscular dystrophy 74 0.17%
Infant lung disease 48 0.11%
TOTAL* 7373 17.04%
Figure 2
Transplant indications where child with stored cord blood does not
have condition
Disease Name Family Family count/
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Most patients with primary immune deﬁciency diseases
(PIDDs) will require a stem cell transplant to cure their
disease. There is, however, no consensus about the best
alternative hemopoietic stem cell donor in the absence of an
HLA-identical source. In particular, there are limited data
comparing the outcomes between PIDD patients receiving
umbilical cord blood transplant (UCBT) versus unrelated
matched stem cell products. Fourteen children, median age 8
months (range, 12 e 20 months) with SCID (n¼11), LAD
(n¼1), reticular dysgenesis (n¼1) or Wiskott-Aldrich syn-
drome (n¼1) received UCBT transplant at our institution
between 2007 and 2013. Five of 14 patients had persistent
viral infections prior to transplant: RSV (n¼2), Parainﬂuenza
3 (n¼1), VZV (n¼1) and Norovirus (n¼1), and 7/14 patients
had requiredmechanical ventilation prior to transplantation.
Seven of 14 patients were 6/6 HLA antigen matched with
their stem cell donor, and 7 were one HLA antigen mis-
matched. All patients received myeloablative conditioning
consisting of busulfan, cyclophosphamide and ﬂudarabine
and one patient also received campath. The median total
nucleated cell dose in the transplant was 10x107/kg (range,
5.9 e 25.4). The median time to neutrophil recovery was 19
days (range, 11-30) and the median time to platelet recovery
was 42 days (range, 27-127). All evaluable patients achieved
full donor chimerism (deﬁned as >95% donor cells in pe-
ripheral blood by day +42). No severe aGVHD or cGvHD has
occurred and only one patient developed grade II aGvHD
(skin). All patients are alive with a median follow up of 2
years (range, 10 days e 6 years). All patients with viral in-
fections at the time of transplant were able to clear the
infection at amedian time of 51 days (range, 44-54) and none
developed signiﬁcant new viral infections after transplant.
ELISPOT analyses of peripheral blood at the time that in-
fections were cleared showed T cell responses against the
pertinent viruses. All evaluable patients have normalization
of their immune defect including adequate B cell function in
SCID patients. Hence, we have shown that UCBT for PIDDs
produces speedy functional engraftment and immune-
reconstitution in the absence of signiﬁcant GvHD, leading to
excellent overall survival. UCBT therefore seems an appro-
priate therapeutic alternative for patients with PIDDs who
lack an HLA matched related donor.count total families
responding
Hodgkin’s lymphoma 142 0.33%
Non-Hodgkin’s lymphoma 137 0.32%
Acute lymphoblastic leukemia 110 0.25%
Sarcoma 66 0.15%
Sickle cell disease 49 0.11%
Acute myelogenous leukemia 39 0.09%
Beta thalassemia major 37 0.09%
Chronic myelogenous
leukemia
37 0.09%
Chronic lymphocytic leukemia 31 0.07%
Neuroblastoma 24 0.06%
Severe aplastic anemia 19 0.04%
Multiple myeloma 18 0.04%
Myelodysplastic syndrome 9 0.02%
Diamond-blackfan anemia 6 0.01%
Fanconi anemia 3 0.01%
Hurler syndrome 0 0.00%
TOTAL* 727 1.68%259
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Background: Little is known about the prevalence of dis-
eases amenable to allogeneic or autologous stem cell in-
fusions among families storing newborn stem cells in private
cord blood banks.
Methods: We surveyed families with at least one child who
had stored newborn stem cells at the largest private cordblood bank in the US. We requested that they complete a
Family Health Questionnaire to determine whether a child
with stored stem cells or a ﬁrst degree relative of that child
currently had one or more of 16 diseases or conditions
amenable primarily to allogeneic stem cell transplant
Figure 3
Regenerative indications where child with stored cord blood has
condition
Disease name Family
count
Family count/total
families responding
Autism/apraxia 859 1.99%
Other developmental delay 609 1.41%
Childhood hearing loss 169 0.39%
Cerebral palsy/periventricular
leukomalacia/hypotonia
116 0.27%
Diabetes, type 1 114 0.26%
Inﬂammatory bowel disease 61 0.14%
Hydrocephalus 53 0.12%
Hypoxic-ischemic brain injury 44 0.10%
In-utero brain injury/stroke 38 0.09%
Infant lung disease 30 0.07%
Traumatic brain injury
(post-delivery)
24 0.06%
Muscular dystrophy 15 0.03%
Spinal cord injury 15 0.03%
Diabetes, type II 5 0.01%
Systemic lupus 3 0.01%
TOTAL* 2155 4.98%
*Families may report more than one condition or disease.
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marily under investigation for autologous stem cell infusion
(“regenerative indications”), regardless of whether they
planned to receive a transplant or infusion.
Results: We received 43,259 completed responses. Of the
families completing the questionnaire, 1.87% reported at
least one transplant indication and 17.04% reported at least
one regenerative indication. Figure 1 shows the total number
and percent of families that reported each of the transplant
and regenerative indications listed. For transplant in-
dications, after subtracting families where the child with the
condition was the family member with stored cells, 1.68% of
families reported at least one indication. The most common
indications reported were Hodgkin’s lymphoma (0.33%),
non-Hodgkin’s lymphoma (0.32%), and acute lymphoblastic
leukemia (0.25%) (Figure 2). Similarly, for regenerative in-
dications, after subtracting families where the child with the
conditionwas not the familymemberwith stored cells, 4.98%
of families reported at least one indication. The most com-
mon indications reported were autism/apraxia (1.99%), other
developmental delay (1.41%), and childhood hearing loss
(0.39%) (Figure 3).
Conclusion: Among families who store newborn stem cells
in private cord blood banks, conditions for which stem cell
transplant or infusion may be indicated or under investiga-
tion are relatively prevalent, especially for regenerative
indications.
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Background: Hematopoietic stem cell transplant (HSCT) is
the only curative option for patients with Diamond-Blackfan
anemia (DBA). However, many patients lack suitable related
or unrelated bone marrow donors. Unrelated cord bloodtransplant (UCBT) has successfully been used to treat many
diseases. Advantages of cord blood include: increased like-
lihood of ﬁnding a suitable graft particularly for racial and
ethnic minorities, rapid availability, lack of risk to the donor,
decreased likelihood of transmitting infections, more
permissive HLA mismatching and decreased incidence of
graft versus host disease (GVHD). Here we describe a cohort
of patients who underwent unrelated umbilical cord blood
transplant (UCBT) for DBA at a single center.
Methods: All patients who underwent UCBT for a diagnosis
of DBA from 1996 to 2011 at Duke University Medical Center
were eligible for this retrospective analysis (n¼6). Patients
were diagnosedwith DBA on the basis of pure red cell aplasia
on bone marrow aspirate and when available by ribosomal
mutation testing (n¼3). Descriptive analysis was used for
measures of engraftment, GVHD and survival.
Results: Patients had a median age of 3.1 years (range: 2.5-
20.3 years), 3 were male and all were caucasian. Prior to
UCBT, patients had a median of 34 (range, 6-230) red cell
transfusions and a median ferritin level of 2213ng/ml (range,
319 e 3328 ng/ml). Five of six patients received busulfan
(1mg/kg/dose x 16), cyclophosphamide (50mg/kg/dose x 4)
and equine Anti-thymocyte globulin (30mg/kg/dose x 3). The
most recent patient received ﬂudarabine (30mg/m2 x 5),
melphalan (70mg/m2 x 2), thiotepa (200mg/m2 x 1), alem-
tuzumab (1mg/kg/dose x 3) and hydroxyurea (30mg/kg/day
x 13). Patients were HLA matched at 4/6 (n¼2), 5/6 (n¼2) or
6/6 (n¼2) using low resolution HLA-A and eB and high
resolution eDRB1 typing. Median total nucleated cell dose
pre-cryopreservation was 9.33x107 cells/kg (range: 2.3-
18.4x107 cells/kg). GVHD prophylaxis was cyclosporine and
steroids. All patients engrafted neutrophils (median 22 days,
range: 19-91 days) and platelets (50K, median 81 days,
range: 41-215 days). Two patients experienced grade II-IV
acute GVHD and one had extensive chronic GVHD. With a
median follow up of 5.5 years (range: 2-14 years), 4 of 6 (67%)
patients are alive and well, full donor chimeras, and free of
transfusions. One patient died at day 70 from veno-occlusive
disease and the second died two years post-transplant from
polyserositis, chronic gut GVHD and kidney failure. None of
the 4 surviving patients suffer from any major chronic
medical problems.
Conclusions: UCBT can successfully be used for the treat-
ment of DBA if otherwise suitable donors are not available.
Survival following UCBT is similar to those reported by
CIBMTR following related and unrelated adult donor trans-
plants for DBA.1
1. Roy, V., et. al. BBMT, 2005, 11(8); 600.261
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Hemophagocytic Lymphohistiocytosis (HLH) is a rare im-
munodeﬁciency disease of early childhood characterized by
immune dysregulation due to impaired cytoxic killing and
uncontrolled activation of T cells and macrophages. HLH can
be congenital or acquired; approximately 40 % of children
have an identiﬁed genetic defect. The standard approach to
HLH is several months of therapy with dexamethasone,
cyclosporin and etoposide to achieve disease control, fol-
lowed by allogeneic hematopoietic stem cell transplant
